IPP Bureau
Acesion Pharma launches Phase 2 trial for groundbreaking atrial fibrillation therapy
By IPP Bureau - January 08, 2026
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Alzheimer’s could soon be detected with a simple finger-prick
By IPP Bureau - January 08, 2026
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Rapid-acting ADHD treatment Azstarys now approved in China
By IPP Bureau - January 08, 2026
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Bayer’s Sevabertinib gets green light from FDA and China for advanced lung cancer
By IPP Bureau - January 08, 2026
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy
By IPP Bureau - January 08, 2026
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Stereotaxis scores FDA nod for groundbreaking MAGiC robotic heart catheter
By IPP Bureau - January 08, 2026
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
By IPP Bureau - January 08, 2026
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Ascletis Pharma gets FDA nod for Phase II diabetes trial of oral GLP-1 drug
By IPP Bureau - January 08, 2026
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
ICMR & Panacea Biotec complete enrollment for India's first indigenous dengue vaccine phase 3 study
By IPP Bureau - January 08, 2026
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Briefs: Medicamen Biotech and Gland Pharma
By IPP Bureau - January 08, 2026
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Wockhardt files marketing authorisation application for WCK 5222 with EMA
By IPP Bureau - January 08, 2026
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Dr. Reddy's launches novel recombinant Hepatitis E vaccine ‘Hevaxin’ in India
By IPP Bureau - January 07, 2026
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Dr. Lal PathLabs launches tech-driven personalized wellness center 'Sovaaka'
By IPP Bureau - January 07, 2026
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
ProBioGen, Zag Bio seal manufacturing deal to fast-track type 1 diabetes therapy into clinic
By IPP Bureau - January 07, 2026
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Subcutaneous Saphnelo cuts lupus disease activity in phase III trial
By IPP Bureau - January 07, 2026
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
